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STUDY PROTOCOL Open Access
Prehospital use of plasma in traumatic
hemorrhage (The PUPTH Trial): study
protocol for a randomised controlled trial
Penny S. Reynolds1*, Mary Jane Michael1, Emily D. Cochran1, Jacob A. Wegelin2 and Bruce D. Spiess1
Abstract
Background: Severe traumatic injury and haemorrhagic shock are frequently associated with disruptions of
coagulation function (such as trauma-induced coagulopathy TIC) and activation of inflammatory cascades. These
pathologies may be exacerbated by current standard of care resuscitation protocols. Observational studies suggest
early administration of plasma to severely-injured haemorrhaging patients may correct TIC, minimise inflammation,
and improve survival. The proposed randomised clinical trial will evaluate the clinical effectiveness of pre-hospital
plasma administration compared with standard- of-care crystalloid resuscitation in severely-injured patients with
major traumatic haemorrhage.
Methods/design: This is a prospective, randomized, open-label, non-blinded trial to determine the effect of
pre-hospital administration of thawed plasma (TP) on mortality, morbidity, transfusion requirements, coagulation, and
inflammatory response in severely-injured bleeding trauma patients. Two hundred and ten eligible adult trauma
patients will be randomised to receive either two units of plasma, to be administered in-field, vs standard of care
normal saline (NS). Main analyses will compare subjects allocated to TP to those allocated to NS, on an intention-
to-treat basis. Primary outcome measure is all-cause 30-day mortality. Secondary outcome measures include
coagulation and lipidomic/pro-inflammatory marker responses, volume of resuscitation fluids (crystalloid, colloid)
and blood products administered, and major hospital outcomes (e.g. incidence of MSOF, length of ICU stay,
length of hospital stay).
Discussion: This study is part of a US Department of Defense (DoD)-funded multi-institutional investigation,
conducted independently of, but in parallel with, the University of Pittsburgh and University of Denver.
Demonstration of significant reductions in mortality and coagulopathic/inflammatory-related morbidities as a
result of pre-hospital plasma administration would be of considerable clinical importance for the management of
haemorrhagic shock in both civilian and military populations.
Trial registration: ClinicalTrials.gov: NCT02303964 on 28 November 2014
Keywords: Bleeding, coagulopathy, inflammatory markers, INR, massive hemorrhage, prehospital, shock, thawed
plasma, TRALI, transfusion, trauma
* Correspondence: psreynolds@vcu.edu
1Department of Anesthesiology, Virginia Commonwealth University Medical
Center, Richmond, VA, USA
Full list of author information is available at the end of the article
TRIALS
© 2015 Reynolds et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Reynolds et al. Trials  (2015) 16:321 
DOI 10.1186/s13063-015-0844-5
Background
Following severe traumatic injury, the immediate care pri-
orities are control of bleeding and correction of the hypo-
volemia and tissue hypoperfusion that result from excessive
blood loss and tissue injury. Massive hemorrhage (MH) re-
quires surgical intervention for definitive hemostasis. How-
ever, trauma-related hemorrhagic shock is also a disease of
ischemic cellular injury and death, resulting from co-
agulation disruption and inflammatory precursor acti-
vation [7, 15, 23]. Approximately 25 % of severely
injured patients present with severely abnormal coagu-
lation changes occurring within very few hours of in-
jury [22]. This so-called trauma-induced coagulopathy
(TIC) is associated with 4-fold increase in mortality, in-
creased rates of late death from sepsis and multiple
organ failure (MOF), and worsened outcomes from
traumatic brain injury (TBI) [4, 5, 13]. Ischemic cellular
injury resulting from uncorrected, persistent, and systemic
hypoperfusion eventually leads to systemic inflammatory
response syndrome and irreversible multi-system organ
failure (MSOF). MSOF is a major cause of late mortality
and morbidity following severe trauma, with a mortality
rate of 50 % to 80 % [20].
To minimize irreversible cell damage and death, it fol-
lows that recognition of MH should occur as soon as
possible after injury and as far upstream as possible from
initiation of coagulopathy/inflammatory cascades. Unfor-
tunately early recognition may not be easily achieved, es-
pecially if bleeding is primarily internal. In practice, the
extent of hemorrhage and shock during the initial as-
sessment stage is based on vital signs, primarily blood
pressure, pulse rate, palpable radial pulses, and menta-
tion [1]. However these are extremely variable, non-
specific, and very poor indicators of perfusion status
[29]. Therefore choice of first-line resuscitation fluids
will be essential for preempting some of the negative
outcomes of unrecognized MH and shock.
There is increased interest in reviving prehospital use
of plasma transfusions for severely injured hemorrhaging
patients, especially if time to definitive care is long. Ob-
servational data suggest improved 6-hr outcomes but no
overall survival advantage with prehospital blood prod-
uct administration [17]. Better patient 30-d survival was
associated with earlier (<4 hr) in-hospital administration
of relatively high ratios of plasma to packed red blood
cells (pRBC) in both civilian [10, 18] and military [3]
trauma populations; meta-analysis supports early use of
plasma but does not conclude that there are additional
survival benefits of 1:1 over 1:2 plasma:pRBC transfusion
ratios [2] In contrast, plasma transfusions have been as-
sociated with increased morbidity and mortality in other
studies of trauma [21] and non-MH patients [24, 26, 27].
However, interpretations of data from these studies may
be confounded by lack of standardization in hospital
resuscitation protocols, changes in transfusion practice
over the past decade, confounding-by-indication bias
[19] and survivor bias [16].
At present there are no data either from systematic re-
views [11] or from completed, prospective, randomized
controlled clinical trials [19] to assess the efficacy of
plasma transfusion alone. Further, there are no rigorous
definitions of how early infusion must occur relative to
injury in order to demonstrate benefit. This study will be
one of three prehospital trials conducted in parallel that
explicitly examines the effect of prehospital plasma trans-
fusion on mortality and morbidity in civilian trauma pa-
tient populations.
Methods/Design
Study design
This study is a prospective, open-label, non-blinded, ran-
domized clinical trial to quantify the effects of early pre-
hospital administration of plasma on death, coagulation
function, transfusion requirements, and other relevant
clinical outcomes for seriously-injured trauma patients
with massive bleeding. Trial flow per the Consolidated
Standards of Reporting Trials (CONSORT) guidelines
[25] is shown in Fig. 1.
Ethical oversight
The study was approved by the Virginia Commonwealth
University Institutional Review Board (VCU-IRB Proto-
col Record HM14813), Food and Drug Administration
(FDA) (IND no. 15910); and the US Department of
Defense (HRPO Log Number A-17160). The study was
listed with the Clinical Trials register on 28 November
2014 (ClinicalTrials.gov number NCT02303964).
Study population
The study population consists of adult, physiologically
unstable, polytrauma patients transported to Virginia
Commonwealth University Medical Center (VCUMC), a
Level I trauma center. The catchment area is Henrico
County and City of Richmond, Virginia. Henrico Fire
EMS system (HFD) serves a population of 325,000 with
over 30,000 transports per year; the city of Richmond
EMS system (Richmond Ambulance Authority, RAA)
serves a metro area of 222,000 with over 27,000 trans-
ports per year.
Inclusion criteria
Patients eligible for this study include all adult (≥18 years)
patients of either sex, with blunt and/or penetrating
trauma with multi-system injuries and unstable vital
signs (systolic blood pressure (SBP) ≤70 mmHg, or SBP
70–90 mmHg with heart rate (HR) ≥108 beats per mi-
nute (bpm)), indicative of severe ongoing hemorrhage.
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Exclusion criteria are: (1) presence of an opt-out wrist
band, wallet card, Medical Alert jewelry, bracelet, or
similar identifier to indicate Jehovah’s Witness or similar
patient group objecting to transfusion of blood and/or
blood products; (2) refusal of consent by patient or legally
appointed representative (LAR); (3) language barrier (non-
English or non-Spanish speaking); (4) not expected to sur-
vive transport to VCUMC (based on extreme severity of
injuries, on-scene cardiac arrest, and/or cardiopulmonary
resuscitation (CPR) prior to randomization); (5) docu-
mented do not resuscitate (DNR) order; (6) isolated
penetrating head trauma; (7) burns to >20 % of the
body surface; (8) pregnancy; (9) prisoner; (10) if patient
transport has proceeded before arrival at the scene by
the emergency medical services (EMS) supervisor with
plasma, and (11) failure of the EMS to obtain intraven-
ous (IV) access.
Patient drop-out
Patients may refuse consent and leave the study at any
time for any reason. Subjects can be withdrawn from the
study emergently by the attending study physician if they
develop signs and symptoms of acute transfusion reaction.
Interventions and controls
Patients will be randomized prior to arrival at the Emer-
gency Department (ED) to receive either thawed fresh-
frozen plasma (TP) or standard-of-care normal saline
(NS) during prehospital transport. Patients randomized
to the TP arm will receive up to two units of pre-thawed
A+ plasma. The control intervention is standard-of-care
NS administered IV/intra-osseous (IO) per prehospital
(ODEMSA) protocol to maintain SBP at 90–100 mmHg.
The VCUMC Blood Bank will provide plasma to EMS
supervisors. Use of low-titer anti-B (<1:100) A+, rather
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of phase progress for the Virginia Commonwealth University (VCU)
plasma trial (PUPTH), a parallel randomized trial of prehospital administration of plasma vs standard-of-care normal saline in a trauma population.
ED Emergency Department
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than AB (universal donor), plasma is justified on the
grounds of the scarcity of AB plasma, and because of the
extremely small risk of hemolytic reaction associated
with administering A+ to patients who are not blood
group compatible (incidence 0.1–1 %) [9]. TP will be
maintained in dedicated refrigeration units in the EMS
supervisor vehicle; unused TP will be exchanged within
24 hr to the VCUMC Blood Bank.
Randomization
Eligible patients will be randomly assigned to receive ei-
ther TP or NS prior to ED arrival. Randomization codes
will be generated using complete randomization; code
sequence is secured by trial statisticians, and held at the
VCUMC Transfer Call Center in sealed opaque enve-
lopes. Patients will be screened for eligibility by on-scene
prehospital providers. Endorsement for plasma adminis-
tration will be given by the study physician on call. At
this point the patient is considered enrolled into the
study. Transfer Centre personnel will then open the next
envelope in sequence and advise EMS as to patient
allocation.
Study outcomes
The primary outcome of this study will be all-cause 30-day
mortality. Secondary outcomes are: (1) hemodynamics
(specifically SBP, mean arterial pressure (MAP), and HR);
(2) cumulative volume of resuscitation fluids and blood
products utilized at 8 and 24 hr from injury (volumes of
crystalloid and/or colloid, units of red blood cells, units of
plasma, doses of platelets, doses of cryoprecipitate); (3)
hematology (hemoglobin (Hb) and hematocrit (Hct)) and
blood biochemistry (pH, lactate, base deficit, and bicarbon-
ate); (4) coagulation function (thromboelastography (TEG),
fibrinogen, FV, FVIII, prothrombin time (PT), activated
partial prothrombin time (aPTT), von Willebrand’s factor,
D-dimer, PFA-100, and platelet count); (5) lipidomic profile
(arachidonic acid, eicosanoid, and prostacyclin expression);
(6) hospital outcomes on days 7 and 30 (rates of MSOF,
rates of acute renal failure (ARF), number of surgeries,
number of infections, duration of mechanical ventilation,
length of ICU stay, and length of hospital stay).
Other data
Patient demographics (age, sex, height, weight, past
medical history, comorbidities, medications), mechanism
of injury, injury severity assessments—Glasgow coma
score (GCS), injury severity score (ISS), sequential organ
failure assessment (SOFA), and acute physiology and
chronic health evaluation (APACHE IV), routine vital
signs and laboratory data, hospital-care-mandated medica-
tions and interventions (e.g., intubation, mechanical venti-
lation, chest thoracotomy, and needle decompression,
etc.)—will be collected from individual medical records as
they become available after patient admission.
Timelines
Follow up of patients enrolled in the trial ends at death
or 30 days post-randomization, whichever occurs first.
Patients discharged before 30 days will be followed up
via telephone by designated study personnel. Blood sam-
ples for coagulation function and lipidomic profiling will
be collected from each patient at four pre-specified time
points: prehospital (close to point of injury, and before
prehospital resuscitation), in the ED (approximately
30 min from hospital admission), and at 8 and 24 hr
from admission.
Estimated event rate and sample size calculations
VCU Trauma Center registry data suggest that 30-day
mortality under the standard-of-care protocol is between
16.4 % and 29.2 %; this is similar to the estimated 26 %
mortality for the control arm of the Resuscitation Out-
comes Consortium (ROC) prehospital hypertonic saline
trial [6]. Assuming 24 % mortality in the control group,
a sample size of 105 per arm will achieve 80 % power to
detect a clinically significant reduction in mortality of
60 % (9.6 % mortality) in the plasma group [12].
Disclosure, consent, and confidentiality protection
Community consultation and public disclosure procedures
Pre-trial public disclosure (required by 21 CFR 50.24)
was completed in 2013–2014. Information was dissemi-
nated by community meetings, web-based and social
media outlets, paid advertisements, and media news re-
leases to TV, radio, and newspapers. Public disclosure
included a summary of investigational plans, background
information about the study, a synopsis of the protocol
and study design, risks and benefits of plasma versus the
standard crystalloid fluid, subject selection, exception
from informed consent requirements, procedures for
contacting LARs, and procedures for declining participa-
tion in the study. Following study termination, findings
of the clinical trial will be disseminated to the commu-
nity by media news releases, the trial website (http://
www.cctr.vcu.edu/news/feature/plasma.html), and rele-
vant patient organizations.
Consent procedures
Significant multi-system trauma with either overt or oc-
cult massive hemorrhage is a life-threatening emergency.
As treatment must be initiated as early as possible, and
severely injured patients may be either unable or not
competent to give fully informed consent, this trial will
be conducted under the Exception from Informed Con-
sent Requirement (21 CFR 50.24). However all reason-
able attempts to impart trial information and obtain
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consent will be made, depending on the urgency of the
immediate medical situation, the mental status of the pa-
tient, and the availability of an LAR or next of kin.
After patient admission, and if the patient is unable to
consent, attempts to contact the LAR or adult next of
kin will be initiated (1) no later than 30 min post-ED ar-
rival, then (2) every 30 min for 2 hr, (3) at least three
more times for the remainder of the first 24 h, (4) at
least twice a day through the end of day 7, and (5) at
least once per week through the end of day 30, death, or
discharge.
Confidentiality will be maintained by securing paper-
based records in a central secure location and electronic
records by access controls and encryption, both to be
accessed only by authorized study personnel. All records
will be de-identified and data coded with the key stored
in a separate secure location.
Post-randomization treatment
All clinically indicated treatments (including blood prod-
uct and fluid administration) will be given as appropriate
per attending physician discretion. Standard of care for
polytrauma patients with MH includes administration of
TP plus blood products and/or crystalloid and colloid
shortly after reaching VCUMC ED, unless otherwise in-
dicated. In addition to administration of trial resuscita-
tion treatments (TP or NS), trial-specific interventions
will include blood sampling for coagulation function and
lipidomic determinations; Approximately 20 mL of blood
will be obtained from each patient at four time points.
Trial management
Stopping rules
It is expected that the trial will terminate when the
intended sample size has been achieved. However, the
trial will be stopped prior to completion if: (1) the inter-
vention is associated with adverse effects that call into
question the safety of the test intervention; (2) problems
with study recruitment or retention will significantly im-
pact the ability to evaluate the study endpoints; (3) any
new information that becomes available during the trial
necessitates discontinuation of the trial. The Principal
Investigator (PI) will include an assessment of futility in
the annual progress report to the FDA (using statistical
means such as predictive probability, if appropriate), and
will consult with the Data and Safety Monitoring Board
(DSMB) to assess the impact of significant data loss due
to problems in recruitment, retention, or data collection.
Trial Steering and Trial Management Committees
The Trial Management Committee consists of the Trial
Steering Committee members plus a Trial Data Manager,
and Trial Financial Administrator (Table 1). Responsibil-
ities include (but are not limited to: (1) maintenance of
trial records; (2) confirmation of regulatory approval
compliance before the start of the trial; (3) provision of
trial-specific training; (4) provision of specialized trial
materials; (5) data management and security; (6) regular
communication with collaborators as to study progress;
(7) safety reporting; (8) statistical analyses, and (9) publi-
cation and dissemination of trial results.
Publication and dissemination of results
The trial protocol and results will be published in peer-
reviewed journals. All publications will follow the CON-
SORT statement [25]. Credit for the study will be
assigned to collaborators who have actually performed
designated work. Links to published data will be pro-
vided through the ClinicalTrials.gov website. The results
of the trial will be reported first to trial collaborators.
Table 1 Members of the Prehospital use of plasma in traumatic hemorrhage (PUPTH) Trial Steering and Management Committees
Name Affiliation Role
Bruce D Spiess, MD Department of Anesthesiology Principal Investigator
Mary-Jane Michael, RN, MS Department of Anesthesiology Trial Coordinator
Chris Hogan, MD Department of Emergency Medicine and Trauma Surgery Clinical expert
Joseph P Ornato, MD Department of Emergency Medicine Clinical expert
Ron Daniel, MD Department of Anesthesiology Trial Safety Officer
Penny S Reynolds, PhD Department of Anesthesiology Trial expert
Emily Cochran, RN, MS Department of Anesthesiology Trial expert
Jacob Wegelin, PhD Department of Biostatistics Trial Statistician
Brian Bush, PhD Department of Biostatistics Data management, IT
Carolyn Jeter Department of Anesthesiology Financial administration
William Aiken, Capt. Henrico Department of Fire EMS
Wayne Barbour Richmond Ambulance Authority EMS
Solomon Luckett Richmond Ambulance Authority EMS
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Dissemination of results to patients will take place via the
media, relevant patient organizations, and the trial website
(http://www.cctr.vcu.edu/news/feature/plasma.html).
Safety and adherence oversight
Data Safety Monitoring Board (DSMB) oversight
An independent DSMB has been appointed to oversee
safety monitoring and trial data (Table 2). DSMB duties
and responsibilities are outlined in the DSMB Charter
tailored specifically for this trial and outlined in accord-
ance with charter guidelines proposed by the DAMO-
CLES Study Group [8]. The DSMB will review cumulative
data at regular intervals over the course of trial, and advise
the TSC apropos the safety of both currently enrolled sub-
jects and those to be recruited. The trial may be termi-
nated early by the Trial Steering Committee and Trial
Safety Officer on recommendation from the DSMB. Study
stopping criteria include futility (significantly increased
risk of serious adverse effects in one of the treatment
groups based on prespecified stopping boundaries for the
primary outcome) and lack of feasibility (e.g., extremely
low patient recruitment, excessive patient dropout, etc.).
Adverse events
Adverse transfusion-related events are extremely rare in
the USA (0.24 % in 2011). Clinical events that are consid-
ered transfusion reactions include: fever (body temperature
change >2 °C), urticaria, pruritis, flushing, hypotension, re-
spiratory distress, bronchospasm, transfusion-related acute
lung injury (TRALI), and transfusion-associated circulatory
overload (TACO) [28].
Study progress and safety will be reviewed weekly by
the Safety Oversight Officer. Assessment and reporting
progress reports will be provided to DSMB; these re-
ports will include numbers for patient recruitment, re-
tention, attrition, and adverse events (AE) and serious
adverse events (SAE). All reported AE will be assessed
for relationship to the study intervention, reviewed as to
treatment arm and further classified by severity (mild,
moderate, severe, life threatening, or disabling), probability
(expected vs unexpected), actions taken, and resolution,
and will be reported to VCU-IRB.
Protocol adherence
Data on adherence to the study protocol will be collected
weekly by research staff and reviewed quarterly by the PI
and the Safety Officer. Weekly adherence will be evaluated
by EMS supervisors and the Trial Safety Officer by moni-
toring four adherence criteria for each enrolled patient:
(1) patient met inclusion criteria, (2) patient was appropri-
ately randomized, (3) patient received appropriate fluid,
and (4) patient had prehospital blood samples drawn.
Scene and transport times are obtained routinely in both
EMS systems, and if feasible will be compared to non‐
protocol case times to assess if protocol adherence results
in unusual delays in time to definitive care. If adherence
falls below the suggested rate of 80 %, which might affect
study integrity in terms of testing the primary hypotheses,
the Safety Officer will suggest a conference call for study
investigators and EMS personnel to discuss methods for
improving adherence. Adherence and deviations from the
study standard operating procedure (SOP) will be re-
ported to the Trial Coordinator and the VCU-IRB.
Data management
The VCU Biostatistics Data Coordinating Group created
standard data entry procedures and systems for web-
based data management during the community consult-
ation phase of the PUPTH trial (completed in 2013), and
will continue to oversee data collection, data entry, and
data quality assurance. This trial will utilize the REDCap
platform for data collection and storage [14]. Staff will
coordinate with the University Computer Center to back
up and archive data daily, and generate reports as re-
quired by the investigators.
Data analyses
Primary analyses will compare primary and secondary
outcomes of patients assigned to either TP or NS on an
intention-to-treat basis. Definitive analyses will occur
after the 30-day observation period for all survivors in
each arm has been completed. Data will be assessed on
de-identified data by statisticians and data analysts
blinded to patient randomization and allocation cat-
egory. Appropriate analysis strategies to reduce effects of
survival and time-dependencies in post-admission treat-
ments will be applied as necessary.
Planned subgroup analyses will be stratified on: (1)
primary mechanism of injury (blunt or penetrating); (2)
injury severity (severe ISS 16–24, critical ISS ≥ 25); (3)
presence or absence of traumatic brain injury, defined by
GCS categories (severe 3–8, moderate 9–12, mild/absent
Table 2 Members of the independent Data Safety and Monitoring Committee
Name Affiliation Expertise
Neil Blumberg, MD University of Rochester Medical Center, New York Clinical expert, DSMB chair
Kevin R Ward, MD University of Michigan School of Medicine, Michigan Clinical expert
Rao Ivatury, MD Virginia Commonwealth University Medical Center, Richmond, Virginia Clinical expert
Roy Sabo, PhD Virginia Commonwealth University School of Medicine, Virginia Independent statistician
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13–15) or by abbreviated injury score-head (AIS-H) cat-
egories (yes ≥3; no <3); (4) presence or absence of severe
shock/tissue hypoperfusion (yes defined by base deficit ≥6
and lactate ≥3 mmol/L; no otherwise). Interaction tests
will be used to examine the effect of the intervention
(if any) across subgroups.
Interim analyses: there will be three planned analyses.
Two interim analyses will be performed following accrual
of 70 patients (35 per arm) and 140 patients (70 per arm),
respectively. Interim and final data will be submitted to
the DSMB for review; stopping criteria are based on safety
data (see Stopping rules). Records will be assessed for data
quality, including completeness (thereby encouraging col-
lection of high-quality data), rates of recruitment and
losses to follow up, and rates of protocol compliance.
Discussion
Benefit of early in-hospital use of TP to correct trauma-
related coagulation dysfunction is weakly supported by
several observational studies [2], but unsupported or
contradicted by other studies [21, 27]. However, con-
founding bias inherent to such studies, coupled with
elastic definitions of what constitutes early in the critical
care timeline, means that these data are not particularly
informative with respect to the immediate care of critic-
ally injured patients in hemorrhagic shock. This study is
designed to assess the efficacy of prehospital plasma re-
suscitation on clinically relevant endpoints of mortality
and short-term coagulation and inflammatory response.
There are several limitations to this study: TP infusion
cannot be blinded to prehospital providers (although
subsequent healthcare professionals may not necessarily
receive this information), variable scene–hospital trans-
port times of 6–30 min, so that not all patients allocated
to the TP arm will receive the full complement of two
units of TP before hospital arrival, and the complexity of
patient management in the field, which means that the
prehospital period will be most vulnerable to missing data.
This trial, coupled with those at Pittsburgh and Denver
sister institutions, will be among the first to test the hy-
pothesis that prehospital plasma administration to se-
verely injured patients is effective in reducing trauma-
related mortality and coagulopathy. Resulting data will
be of considerable clinical importance for informing the
management of hemorrhagic shock in both civilian and
military populations.
Trial status
The trial has begun enrolling patients. The expected aver-
age enrollment rate is one patient per week until 2016.
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